Key facts

You can download a factsheet on the company which highlights our performance over the last 12 months here.

March 2013 - First product in cough cold pipeline achieves proof-of-concept

March 2013 - Vernalis and Servier extend oncology collaboration

March 2013 - Vernalis earns further $2.5m payment from Genentech collaboration

February 2013 - Vernalis earns $1.5 million milestone in Genentech collaboration

January 2013 - Vernalis earns €0.75 million milestone in third Servier collaboration

January 2013 - Vernalis earns £0.75 million milestone in Lundbeck collaboration

December 2012 - Positive results achieved in Receptor Occupancy Study of V81444

September 2012 - Vernalis earns €1.0 million milestone in Servier collaboration

August 2012 - Receptor Occupancy Study of V81444 initiated

May 2012 - Successful outcome of V81444 Phase I study

April 2012 - Vernalis earns €0.5 million milestone in Servier collaboration

February 2012 - Licensing deal with Tris Pharma and associated £65.9 million equity fundraising announced

January 2012 - Third oncology collaboration with Servier signed

January 2012 - Drug discovery collaboration announced with Genentech

December 2011 - Vernalis and Lundbeck achieve a second research milestone and Vernalis receives a £0.4 million payment

December 2011 - Vernalis earns a final milestone payment of US$1.9 million from Ipsen

October 2011 - Vernalis and Servier achieve research milestone and their first oncology collaboration is extended

September 2011 - Positive results achieve in V158866 Phase I study in pain

September 2011 - Vernalis and Lundbeck acheive a research milestone

August 2011 - Vernalis initiates Phase I trial of V81444 for Parkinson's Disease 

July 2011 - AUY922 included for the first time in Novartis' selected pharmaceutical pipeline project chart.

April 2011 – Vernalis regains rights to V81444 from Biogen Idec, Phase I ready programme with MHRA approval

March 2011 – Vernalis initiates Phase I trial of V158866 for pain

March 2011 – Licensing deal signed by Chroma Therapeutics for North, Central and South America.  Orphan drug status for AML granted by US FDA and EMA

December 31 2010 – Cash resources of £30.9 million

December 2010 – Vernalis signs research collaboration with Lundbeck

November 2010 – Investment in V3381 discontinued

October 2010 – Vernalis earns €0.75 million milestone in second oncology collaboration with Servier

July - 2010 – A2A programme switched to next generation compound

May 2010 – Vernalis extends first oncology collaboration with Servier

March 2010  – Vernalis announces V3381 phase IIb study results – V3381 misses primary endpoint in neuropathic pain

March 2010 – Novartis starts phase II proof of concept clinical trial of AUY-922 triggering a $3m milestone receipt

February 2010 – Vernalis regains rights to 100% of the frovatriptan EU royalties from Paul Capital

February 2010 – Vernalis raises £30 million (£28.5 million net of expenses) through a Placing and Open Offer

December 2009 – Vernalis earns a milestone receipt in connection with the 2008 sale of Apokyn and its US commercial operations

October 2009 – Vernalis initiates a pilot study of V3381 in chronic cough

September 2009 - V3381 phase IIb enrolment complete

August 2009 – research collaboration option and licence with GSK signed, generating $US 6 million up front with potential milestone income in excess of US$200 million

July 2009 – Vernalis announces a new oncology development target – V158411

July 2009 – Novartis starts Phase I trial of HSP990, triggering a $1.5 million milestone receipt

June 2009 – Vernalis’ partner secures approval for frovatriptan in Korea

May 2009 – three-year collaboration signed with Servier against an undisclosed oncology target

April 2009 – Vernalis raises £22.1 million (net of expenses) through a Placing and Open Offer

November 2008 – Appointment of new management team – Ian Garland and David Mackney to join from Acambis plc